AstraZeneca Overview

  • Year Founded
  • 1913

Year Founded

  • Status
  • Public

  • Employees
  • 94,300

Employees

  • Stock Symbol
  • AZN

Stock Symbol

  • Investments
  • 125

  • Share Price
  • $133.96
  • (As of Thursday Closing)

AstraZeneca General Information

Description

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Contact Information

Website
www.astrazeneca.com
Formerly Known As
Astra AB, Zeneca Group Plc
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 1 Francis Crick Avenue
  • Cambridge Biomedical Campus
  • Cambridge CB2 0AA
  • England, United Kingdom
+44 020
Primary Industry
Pharmaceuticals
Stock Exchange
LON
Vertical(s)
Manufacturing, Life Sciences, Oncology
Corporate Office
  • 1 Francis Crick Avenue
  • Cambridge Biomedical Campus
  • Cambridge CB2 0AA
  • England, United Kingdom
+44 020

AstraZeneca Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AstraZeneca Stock Performance

As of 17-Apr-2025, AstraZeneca’s stock price is $133.96. Its current market cap is $208B with 1.55B shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$133.96 $135.65 $122.42 - $175.93 $208B 1.55B 2.84M $4.54

AstraZeneca Financials Summary

As of 31-Dec-2024, AstraZeneca has a trailing 12-month revenue of $54.1B.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 230,353,364 230,353,364 232,662,483 233,963,613
Revenue 54,073,000 54,073,000 45,811,000 44,351,000
EBITDA 15,093,000 15,093,000 13,121,000 9,004,000
Net Income 7,035,000 7,035,000 5,955,000 3,288,000
Total Assets 104,035,000 104,035,000 101,119,000 96,483,000
Total Debt 30,114,000 30,114,000 28,407,000 29,143,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AstraZeneca Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AstraZeneca‘s full profile, request access.

Request a free trial

AstraZeneca Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells brand
Pharmaceuticals
Cambridge, United Kingdom
94,300 As of 2024

Middlesex, United Kingdom
 

Rahway, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AstraZeneca Competitors (35)

One of AstraZeneca’s 35 competitors is GSK, a Corporation company based in Middlesex, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GSK Corporation Middlesex, United Kingdom
Merck & Co. Corporation Rahway, NJ
Novartis Corporation Basel, Switzerland
Pfizer (Pharmaceuticals) Corporation New York, NY
AbbVie Corporation North Chicago, IL
You’re viewing 5 of 35 competitors. Get the full list »

AstraZeneca Patents

  • 29,825

    Total Documents Applications and Grants

  • Total Patents Families

  • 7,710

    Granted

  • 2,380

    Pending

  • Expiring in next 12 mo

AstraZeneca Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202416572-D0 Novel compounds Pending 11-Nov-2024
GB-202415645-D0 Compounds and their use Pending 24-Oct-2024
GB-202410225-D0 Novel compounds Pending 12-Jul-2024
GB-202409123-D0 Assays for identifying binding molecules Pending 25-Jun-2024
GB-202408335-D0 Therapies for wound treatment Pending 11-Jun-2024
To view AstraZeneca’s complete patent history, request access »

AstraZeneca Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AstraZeneca Investments & Acquisitions (125)

AstraZeneca’s most recent deal was a PIPE with Harbour BioMed for . The deal was made on 21-Mar-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Harbour BioMed 21-Mar-2025 PIPE Drug Discovery
EsoBiotec 17-Mar-2025 Merger/Acquisition Biotechnology
FibroGen (China) 20-Feb-2025 Merger/Acquisition Drug Discovery
Achilles Therapeutics (TRACERx and MAP Assets) 24-Dec-2024 Corporate Asset Purchase Buildings and Property
Syneron Tech 19-Nov-2024 Early Stage VC Biotechnology
You’re viewing 5 of 125 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

AstraZeneca ESG

Risk Overview

Risk Rating

Updated January, 15, 2025

21.75 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,109

Rank

Percentile

Pharmaceuticals

Industry

of 861

Rank

Percentile

Pharmaceuticals

Subindustry

of 430

Rank

Percentile

To view AstraZeneca’s complete esg history, request access »

AstraZeneca Exits (30)

AstraZeneca’s most recent exit was on 07-Aug-2023 from 66Nao Brain Training. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
66Nao Brain Training 07-Aug-2023 Completed
  • 2 buyers
VaxEquity 23-Sep-2021 Completed
  • 2 buyers
Dizal Pharma 23-Dec-2019 Completed
  • 2 buyers
Dizal Pharma 28-May-2019 Completed
  • 2 buyers
Corvidia Therapeutics 25-Apr-2018 Early Stage VC Completed
  • 10 buyers
You’re viewing 5 of 30 exits. Get the full list »

AstraZeneca Affiliates

Subsidiaries (30)

Name Industry Location Year Founded
Astrazeneca Reims Production Reims, France 2020
Portola Frg Munich, Germany 2019
Gracell Shanghai, China 2017
Icosavax Seattle, WA 2017
Portola Pharma Uk Uxbridge, United Kingdom 2015
You’re viewing 5 of 30 affiliates. Get the full list.  »

AstraZeneca FAQs

  • When was AstraZeneca founded?

    AstraZeneca was founded in 1913.

  • Where is AstraZeneca headquartered?

    AstraZeneca is headquartered in Cambridge, United Kingdom.

  • What is the size of AstraZeneca?

    AstraZeneca has 94,300 total employees.

  • What industry is AstraZeneca in?

    AstraZeneca’s primary industry is Pharmaceuticals.

  • Is AstraZeneca a private or public company?

    AstraZeneca is a Public company.

  • What is AstraZeneca’s stock symbol?

    The ticker symbol for AstraZeneca is AZN.

  • What is the current stock price of AstraZeneca?

    As of 17-Apr-2025 the stock price of AstraZeneca is $133.96.

  • What is the current market cap of AstraZeneca?

    The current market capitalization of AstraZeneca is $208B.

  • What is AstraZeneca’s current revenue?

    The trailing twelve month revenue for AstraZeneca is $54.1B.

  • Who are AstraZeneca’s competitors?

    GSK, Merck & Co., Novartis, Pfizer (Pharmaceuticals), and AbbVie are some of the 35 competitors of AstraZeneca.

  • What is AstraZeneca’s annual earnings per share (EPS)?

    AstraZeneca’s EPS for 12 months was $4.54.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »